Researchers mine data and connect the dots about processes driving neuroblastoma

October 14, 2020

(MEMPHIS, TENNESSEE - October 14, 2020) Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors. The findings revealed possible approaches for developing precision medicines to improve patient outcomes. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Nature Communications.

The analysis involved whole genome, whole exome and whole transcriptome sequencing of 702 neuroblastoma samples. The tumors included 23 samples from patients who relapsed. The work identified associations among common mutational traits that researchers hope to exploit therapeutically.

"This combined analysis of a large cohort of tumors provided insight into previously unrecognized correlations at work in neuroblastoma as well as the discovery of less common driver mutations," said corresponding author Jinghui Zhang, Ph.D., chair of the St. Jude Department of Computational Biology.

The co-corresponding authors are Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator, and Michael Hogarty, M.D., of the Children's Hospital of Philadelphia.

Connecting the dots between common mutations and oxidative stress

Researchers used a common mutational pattern almost like a fingerprint to identify internal processes fueling the tumor's growth and spread. Investigators knew DNA-damaging molecules called reactive oxygen species and oxidative stress are elevated in neuroblastoma. Reactive oxygen species are generated in the mitochondria of cells. The analysis found an association between a chromosomal mutation in 65% of neuroblastomas and the DNA-damaging molecules. These tumors have an extra piece of chromosome 17. That piece includes genes expressed in the mitochondria. The results suggest that mitochondrial gene defects may lead to increased production of reactive oxygen species, fueling tumor growth and drug resistance.

A St. Jude Cloud search of more than 1,000 pediatric tumor genomes from 39 cancer types found the association was not unique. Researchers reported that more than 20% of samples from another cancer, rhabdomyosarcoma, had increased expression of mitochondrial genes and a pattern of increased oxidative stress. The finding strengthened the newly identified connection between mitochondrial gene defects and the mutational process.

"Thanks to this analysis, we have a deeper understanding of the alterations driving neuroblastoma, including how tumors form, progress and respond to therapy," Dyer said. "That is the foundation for translational research going forward."

Neuroblastoma predictors

Neuroblastoma develops in fetal nerve cells called neuroblasts that fail to mature normally. While 7 to 10% of childhood cancers are neuroblastoma, the tumor accounts for half of all cancers in infants. This cancer generally begins in the adrenal glands, but it can also start in the chest, the spine or spinal cord regions, abdomen and other areas.

Treatment and outcomes vary widely based on patient age. Survival rates for the youngest patients (younger than 18 months old) are about 95%. For older, high-risk patients, survival rates are only about 50%.

This study reinforced the association between patient age and the mutations driving the disease. For example, the genes MYCN and TERT were commonly altered in patients 3.8 years of age or younger while mutations in ATRX were more frequent in children with a median age of 5.6 years.

MYCN, ATRX and a "beautiful convergence"

The analysis offered insight into previous research from Dyer and his colleagues. The researchers noted that while MYCN or ATRX were potent drivers of neuroblastoma, the mutations did not occur together.

"In most cancers, you would expect to find patients with both mutations who did even worse," Dyer said. "But we never found this combination, which was a surprise."

Dyer said this analysis suggests why. MYCN and ATRX mutations induce oxidative stress. Dyer hypothesized that, when combined, the mutations may be lethal to tumor cells.

"This was a beautiful convergence of two different approaches to understanding the mutational processes underway inside cells," he said.

Recurring, but less common gene alterations The analysis included data from St. Jude, including the St. Jude-Washington University Pediatric Cancer Genome Project; the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, managed by the National Cancer Institute; and the Children's Oncology Group, a clinical cooperative trials group.

The large number of samples aided efforts to find recurring, but less common neuroblastoma alterations that may be candidates for precision medicines. The newly identified mutations were in the genes FGFR1 and ALK.
-end-
Samuel Brady, Ph.D., and Yanling Liu, Ph.D., of St. Jude are the first authors. The other authors are Xiaotu Ma, Alexander Gout, Kohei Hagiwara, Xin Zhou, Jian Wang, Michael Macias, Xiaolong Chen, John Easton, Heather Mulder, Michael Rusch, Lu Wang, Joy Nakitandwe, Shaohua Lei, Eric Davis, Cheng Cheng and James R. Downing, of St. Jude; Arlene Naranjo, University of Florida; John Maris, The Children's Hospital of Philadelphia; and Nai-Kong Cheung, Memorial Sloan Kettering Cancer Center, New York.

The research was funded in part by grants (CA021765, CA216391-01A1, CA220500, CA180899) from National Cancer Institute of the National Institutes of Health; and ALSAC, the St. Jude fundraising and awareness organization.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food -- because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.

St. Jude Children's Research Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.